The liposomal plasmids and liposomal viruses as carriers of therapeutic genes, discovered by Dr. Boulikas, are able to target tumors and metastases, inflammatory arteries and arthritic joints.
He has contributed to systemic viral delivery using a mechanism that evades immune responses, results in long circulation and protects virus from destruction in human sera thus solving a major hurdle in clinical gene therapy; using regulatory DNA sequences. Dr. Boulikas has contributed to tumor-specific _expression of toxic genes.
Dr. Boulikas is the founder of Regulon, Inc. (1997, a California Corporation), founder of Regulon-Gonidiaki AE (2001, a Hellenic Corporation) and co-founder of Cancer Therapeutics Sciences (2004, a Swiss Corporation). He has also made breakthroughs in wound healing and treatment of burns in Hospitals (www.burnhealing.com); he is the inventor of a series of innovative dermaceuticals to be marketed as Dermols in 2004-2007 for the treatment of acne, diabetic ulcers, psoriasis, genital infections, ear infections, athlete's foot syndrome, and for the treatment of the hand and foot syndrome and peripheral neuropathies caused by chemotherapy.
His passion is lab work on liposomal drugs, on therapeutic genes and regulatory DNA to fight human disease. Teni Boulikas, Ph.D., holds a B.Sc. degree in Chemistry from the Aristotelian University of Thessaloniki (Greece). He received his Ph.D. from the Southwestern Medical School in Dallas, Texas in Biochemistry. The major effort of his work demonstrated a contact between the H1 molecule and histone H2A that has been a milestone in chromatin research with important implications on the molecular mechanisms of chromatin condensation. As a European Molecular Biology Organization postdoctoral Fellow, he studied nuclear matrix-chromatin interaction at the Swiss Institute for Experimental Cancer Research in Lausanne. He determined contacts between the lamin proteins and DNA and he developed a highly sensitive silver staining method applicable to both proteins and nucleic acids, a work with over 3,000 citations.
Teni became Assistant Professor of Biochemistry and headed one of the Laboratories at the University of Sherbrooke in Quebec with research activities on immunoglobulin genes and other important areas related to antibodies. He then moved to the Linus Pauling Institute in Palo Alto as an Investigator and Director of the Laboratory of Molecular Carcinogenesis and later at the Institute of Molecular Medical Sciences (Palo Alto). In 1996 he was appointed Consultant to SEQUUS Pharmaceuticals. He has 64 publications.
Since 1997 Dr. Boulikas works at Regulon (Mountain View, California and Athens, Greece) as Chairman of the Board and CEO with research activities focusing on liposomal encapsulation of drugs and on isolation of Matrix Attachment Regions as a method for providing the enhancers, origins of replication, and promoter regions from mammalian genomes and their use to enhance the expression of genes in gene therapy applications.
In 2003 he received a world patent on encapsulation of cisplatin, other structurally unrelated drugs and genes that formed the novel platform technology of Regulon. Dr. Boulikas is the organizer of 8 International Conferences aiming at bridging the fields of Gene Therapy and Molecular Biology & Medicine. He is the Founder of the International Society of Gene Therapy and Molecular Biology. His professional responsibilities include managing patient data, promoting the clinical trials of Regulon in several countries and assembling the most exciting teams of oncologists as Regulon's collaborators.
We are especially honored with Teni’s interest in the Alzheimer's CURE Foundation, Inc., his faith in and commitment to our mission, and the fact that he so readily accepted his nomination to our Board of Directors despite his overwhelming schedule.
